Take­da swoops in and scoops up a cell ther­a­py start­up in buy­out deal, ex­pand­ing on­col­o­gy pipeline

A lit­tle more than 4 years af­ter Take­da stepped in to help bankroll the T cell start­up Gam­maDelta Ther­a­peu­tics with a cool $100 mil­lion in­jec­tion, the glob­al phar­ma play­er is get­ting off the side­lines and buy­ing the biotech for it­self.

Take­da ex­ecs said Wednes­day that they will “ob­tain Gam­maDelta’s al­lo­gene­ic vari­able delta 1 (Vδ1) gam­ma-delta (γδ) T cell ther­a­py plat­forms, which in­cludes both blood-de­rived and tis­sue-de­rived plat­forms, in ad­di­tion to ear­ly-stage cell ther­a­py pro­grams.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN